Biologic Infection-Risk Screening: Understanding Latent…

What Biologic Infection-Risk Screening Is

Biologic infection-risk screening refers to a series of diagnostic tests performed before starting biologic therapy, particularly in the context of psoriasis. These screenings aim to identify any latent infections that could reactivate during or after treatment with biologics.

The primary focus is on tuberculosis (TB) and hepatitis B virus (HBV), as these are common latent infections that can pose significant risks when activated by immunosuppressive therapies.

Why It Matters

Screening for latent infections before initiating biologic therapy is crucial because biologics work by modulating the immune system, which can inadvertently reactivate dormant pathogens. Reactivation of these infections can lead to severe complications and prolonged treatment regimens.

By identifying and managing potential reactivation risks early, healthcare providers can minimize the risk of adverse outcomes and ensure better patient safety.

live demo · related simulation● LIVE

How It Works

The screening process typically involves a combination of blood tests to detect specific markers of latent infections. For TB, this includes tuberculin skin tests or interferon-gamma release assays (IGRAs). For HBV, serological tests are used to check for the presence of viral antigens and antibodies.

In some cases, additional imaging studies such as chest X-rays may be required to rule out active TB infection.

Real-World Examples

For instance, a patient with latent TB who is about to start biologic therapy would undergo a tuberculin skin test or IGRAs. If the tests are positive, appropriate treatment for latent TB must be initiated before starting the biologics.

Similarly, patients at risk of HBV reactivation might receive prophylactic antiviral medications to prevent the virus from becoming active during and after biologic therapy.

Frequently asked questions

Why is screening for latent infections important before starting biologics?

Screening helps identify potential reactivation of dormant infections, which can lead to serious complications if not managed properly. It ensures that patients are in a safe state before initiating immunosuppressive therapy.

What happens if latent TB is detected during screening?

If latent TB is detected, the patient will receive appropriate treatment for latent TB before starting biologic therapy to prevent reactivation of the infection.

Can all latent infections be screened for before starting biologics?

Typically, screening focuses on common latent infections like tuberculosis and hepatitis B. Other latent infections may not always be included due to less frequent occurrence or lower risk in specific patient populations.

Is the screening process painful or invasive?

The screening process is generally non-invasive. Tests such as blood draws, skin tests, and IGRAs are routine procedures that do not cause significant discomfort to the patient.

Try it live

Everything above runs in your browser — open Biologic Infection-Risk Screening Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.

▶ Open Biologic Infection-Risk Screening Simulator simulation

Biologic Infection-Risk Screening: Understanding Latent Infections in Psoriasis Therapy